Clinicopathological profile of female genital tract malignancies reported at a tertiary care center in Northern India

Introduction

Female genital tract (FGT) is the site of large number of tumours of considerable diversity, some very common and some extremely uncommon. However due to lack of cancer awareness and effective screening programmes in most developing countries including India, these malignancies constitute a major health burden.^[1], ^[2] Also these tumours have dissimilar pattern of distribution and clinical presentation worldwide with ethnic, environmental and geographic variation. However the data relating to the clinicopathological characteristics of these tumours is deficient from Indian subcontinent indicating significant knowledge gap. An attempt is therefore made in the present study to assess the relative proportions and clinicopathological characteristics of FGT malignancies in our institution by a descriptive prospective histopathological study.

Materials and Methods

All cases reported at our center or referred to it and treated in the Department of Gynaecology over a period of 2 years were reviewed. The clinical data was collected from patient record files, discharge books and pathology request forms. From these data sources, age at diagnosis, clinical presentation at diagnosis, part of FGT affected and histopatholological characteristics were extracted. The data were entered into a computerized spreadsheet and analysis performed using Advanced Excel Sheet. Frequency distributions and descriptive statistics were calculated for each variable.

Results

Spectrum of FGT malignancies

A total of 175 cases of FGT malignancies were reported during the period under study. The anatomical distribution of these malignancies were: Cervix 123 (70.3%), Ovary 30 (17.1%), Uterus 11 (6.3%), Vagina 4 (2.3%), Vulva 5 (2.9%) and Fallopian tube 2 (1.1.%). Thus, cervix was the most common and fallopian tube the least common site of FGT malignancy in our study ([Table 1]).

Site of tumour	No. of cases	Percentage
Cervix	123	70.3
Ovary	30	17.1
Uterus	11	6.3
Vagina	4	2.3
Vulva	5	2.9
Fallopian tube	2	1.1
Total	175	100

Table 1 Distribution of cases of FGT malignancy according to site

Age distribution of various subtypes of FGT malignancies

The ages of 175 women with FGT malignancies ranged from 10-69 years with a mean of 50.7 years. Majority of FGT malignancies (35.4%) were seen in the sixth decade, followed by 27 % cases in fifth decade and 23.4% cases in the seventh decade onwards. It was noted that the FGT malignancies were rare before the age of 20 years ([Table 2]).

Age group (years)	No. of malignant cases	Percentage
<20	2	1.1
20-29	6	3.4
30-39	17	9.7
40-49	47	27
50-59	62	35.4
≥60	41	23.4
Total	175	100

Table 2 Distribution of cases of FGT malignancies according to different age groups

The ages of 123 women with malignancies of cervix ranged from 28-69 years with maximum number of cases 44(35.7%) in the age group of 50-59 years and a mean age of 51.1 years. The ages of 30 women with ovarian malignancies ranged from 18-65 years with maximum number of cases in the age group of 40-49 years and a mean age of 46.5 years. The ages of 11 women with malignancies of uterus ranged from 37-68 years with maximum number of cases 5(45%) in the age group of 60-69 years and a mean age of 54.5 years. The ages of 4 women with malignancy of vagina ranged from 55-67 years with maximum cases 3(75%) in the age group of 50-59 and a mean age of 57 years. The age of 5 women with vulval malignancy ranged from 48-68 years with maximum number of cases 3(60%) in the age group of 50-59 years and a mean age of 54.5 years. The age of 2 women with fallopian tube malignancy ranged from 47-56 years with 1 case each in the age group of 40-49 years and 50-59 years ([Table 3]).

Age group (years)	Cervix	Ovary	Uterus	Vagina	Vulva	Fallopian tube
<20	0	2	0	0	0	0
20-29	3	3	0	0	0	0
30-39	13	2	2	0	0	0
40-49	35	9	1	0	1	1
50-59	44	8	3	3	3	1
≥60	28	6	5	1	1	0
Total	123	30	11	4	5	2

Table 3 Age wise distribution of individual malignant tumours of FGT

Discussion

During the period of 2 years under study, a total of 175 cases of FGT malignancies were diagnosed in our institution; out of which majority were from cervix (70.3%), followed by ovary (17.1%), uterus (6.3%), vulva (2.9%), vagina (2.3%) and fallopian tube (1.1%). This supports previous institutional based studies from other developing countries that found the commonest FGT malignancy to be cancer of uterine cervix.^[3], ^[4], ^[5], ^[6], ^[7], ^[8] However the pattern of malignancy in our study differs from a study by Momtahen in Iran that showed a higher incidence of endometrial cancer (58%) and lesser prevalence of cervical cancer (13.6%).^[9] The prevalence of cervical cancer in the current study, like in other developing countries has been attributed to the high prevalence of child marriage, early sexual activity, ignorance and lack of effective cancer screening programmes.

The mean age of women diagnosed with cancer of cervix was 51.9 years and maximum cases were in the age group of 50-59 years. However the data from Surveillance, Epidemiology and End Results Program of United States and European Union showed significantly higher proportion of cervical malignancies in the younger age group as compared to those reported at our center.^[10] This may be a manifestation of better screening programmes in the US where cervical malignancy is detected in younger patients at a localized stage.

In the current study, the most common clinical presentation of women with carcinoma cervix was bleeding per vaginum; similar to other previous studies.^[11], ^[12]

The most common histological subtype of cervical cancer was SCC (87%), followed by adenocarcinoma (8.2%) and adenosquamous carcinoma (1.6%). This was in concordance with the study of Shingleton et al ^[13] who has reported 83.8% cases of cervical carcinoma as SCC, 12.6 % as adenocarcinoma and 3.6% as adenosquamous carcinoma.

Ovary was the second leading site among FGT malignancies at our centre; constituting 17.1% of total FGT malignancies. This is in accordance with the data from Globocon 2002 which also shows a relatively higher incidence of ovarian malignancies in the West; similar to data from NCRP and other cancer registries in India.^[14], ^[15], ^[16]

Most of the cases of ovarian malignancy occurred in the fifth decade and the mean age was 46.5 years. Yeole et al^[17] have also reported maximum number of ovarian malignancies in the age group of 45-55 years.

The most common presenting complaint in cases of ovarian malignancy was lump in abdomen (80%), followed by pain in abdomen (73.3%). This corresponded with the findings of Maheshwari et al^[18] who also found abdominal lump as presenting feature in 71.9% cases, followed by pain in abdomen in 47.4% cases.

Serous cystadenocarcinoma was the commonest malignant tumour of ovary in this study which accounted for 53.3% of malignant ovarian tumours. Katzenstein et al^[19] found that that borderline and invasive tumours together constituted 35-40% of all malignant ovarian tumours.

In our study, carcinoma of uterine corpus was the third most common site of malignancy constituting 6.3% of all FGT malignancies. Jamal et al^[20] also reported uterine malignancy to be the third most common amongst the gynaecological malignancies with an incidence of 16%.

Endometrial cancer is the cancer of post-menopausal females. The study showed maximum cases of endometrial carcinoma in the sixth decade and the mean age was 54.5 years. This was consistent with the findings of Jamal et al^[20] who has reported the mean age of patients with endometrial carcinoma as 52.5 years.

The most common complaint of the patients of endometrial carcinoma in this study was abnormal uterine bleeding which was observed in 81.8% cases. Similar findings were reported by Hacker et al.^[21]

Amongst the various histological subtypes of uterine malignancy, endometrioid adenocarcinoma was the most frequent type constituting 82% of all cases. Similar findings were observed by Platz et al^[22] who reported it to be 81.5%.

Vagina, vulva and fallopian tubes were the less common sites of malignancy when compared to other sites of FGT. In the current study, the proportion of malignancy in these sites were reported to be 2.3%, 2.9% and 1.1% respectively of the total FGT malignancies. This finding suggests that cancer of vulva and vagina are not rare malignancies as determined in some studies.^[23], ^[24] In the current study, fallopian tube (1.1%) was the least common site of malignancy in FGT. This differs from a study in Nigeria which reported vagina to be the least prevalent cancer of the FGT.^[25]

The cases of vaginal, vulval and fallopian tube malignancy were reported in the fifth decade onwards. The mean age of diagnosis in vagina was 57 years, vulva 54.5 years and fallopian tube 49.5 years. This was in accordance with the findings of Jamal et al^[20] who has reported these cases in the age group of 40-60 years.

Women with vaginal cancer and vulval cancer presented with ulcers and mass, similar to other studies. This differs from a study on vaginal cancer that reported bleeding per vaginum as the most frequent mode of presentation.^[26]

In our study, squamous cell carcinoma constituted 60% cases of vulval and 75% cases of vaginal malignancy. This was in accordance with the findings of Platz et al^[22] who also reported SCC to be the most common malignancy of vulva and vagina constituting 74.4% and 70.8% respectively.

In our study, 25% cases of vaginal malignancy were clear cell adenocarcinoma. Beller et al^[27] have reported vaginal adenocarcinoma in 14% cases.

Both the cases of fallopian tube malignancy in this study were serous adenocarcinoma, one primary and the other metastatic. Baekelandt et al^[28] have also reported serous adenocarcinoma as the most common malignancy of fallopian tube.

Conclusion

Although cancers of FGT are an important cause of morbidity and mortality among women worldwide; but there is significant lacunae in the FGT cancer detection programmes in India. So larger and more detailed study on the trends of FGT cancers is essential to plan better cancer detection strategies for specific age groups at risk.

Conflict of Interest

The authors declare that there are no conflicts of interest in this paper.

Source of Funding

None.